Alector, Inc.

NasdaqGS:ALEC Stock Report

Market Cap: US$158.3m

Alector Management

Management criteria checks 3/4

Alector's CEO is Arnon Rosenthal, appointed in Jan 2013, has a tenure of 12.92 years. total yearly compensation is $3.67M, comprised of 18.4% salary and 81.6% bonuses, including company stock and options. directly owns 5.19% of the company’s shares, worth $8.22M. The average tenure of the management team and the board of directors is 3.9 years and 6 years respectively.

Key information

Arnon Rosenthal

Chief executive officer

US$3.7m

Total compensation

CEO salary percentage18.41%
CEO tenure12.9yrs
CEO ownership5.2%
Management average tenure3.9yrs
Board average tenure6yrs

Recent management updates

Recent updates

Alector Stock Down After Latozinemab Failure, Eyes On Phase 2 Catalyst

Dec 16

Alector, Inc.'s (NASDAQ:ALEC) Shares Bounce 32% But Its Business Still Trails The Industry

Sep 16
Alector, Inc.'s (NASDAQ:ALEC) Shares Bounce 32% But Its Business Still Trails The Industry

This Just In: Analysts Are Boosting Their Alector, Inc. (NASDAQ:ALEC) Outlook for This Year

Aug 13
This Just In: Analysts Are Boosting Their Alector, Inc. (NASDAQ:ALEC) Outlook for This Year

Alector, Inc.'s (NASDAQ:ALEC) Shares Bounce 29% But Its Business Still Trails The Industry

Jul 24
Alector, Inc.'s (NASDAQ:ALEC) Shares Bounce 29% But Its Business Still Trails The Industry

US$5.26 - That's What Analysts Think Alector, Inc. (NASDAQ:ALEC) Is Worth After These Results

May 11
US$5.26 - That's What Analysts Think Alector, Inc. (NASDAQ:ALEC) Is Worth After These Results

Alector, Inc. (NASDAQ:ALEC) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

May 05
Alector, Inc. (NASDAQ:ALEC) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
User avatar

ABC Platform And Latozinemab Trial Will Yield Mixed Prospects

Alector's ABC platform and late-stage trials, like those for latozinemab, could significantly boost revenue if successful, addressing unmet medical needs.

Alector, Inc. (NASDAQ:ALEC) Not Doing Enough For Some Investors As Its Shares Slump 26%

Mar 21
Alector, Inc. (NASDAQ:ALEC) Not Doing Enough For Some Investors As Its Shares Slump 26%

Alector: Q4 Of 2025 FTD-GRN Treatment Data Is Important Inflection Point

Mar 13

Earnings Update: Alector, Inc. (NASDAQ:ALEC) Just Reported And Analysts Are Trimming Their Forecasts

Mar 01
Earnings Update: Alector, Inc. (NASDAQ:ALEC) Just Reported And Analysts Are Trimming Their Forecasts

The Market Doesn't Like What It Sees From Alector, Inc.'s (NASDAQ:ALEC) Revenues Yet As Shares Tumble 53%

Dec 23
The Market Doesn't Like What It Sees From Alector, Inc.'s (NASDAQ:ALEC) Revenues Yet As Shares Tumble 53%

Need To Know: Analysts Just Made A Substantial Cut To Their Alector, Inc. (NASDAQ:ALEC) Estimates

Nov 28
Need To Know: Analysts Just Made A Substantial Cut To Their Alector, Inc. (NASDAQ:ALEC) Estimates

Alector: Bleak Prospects After Alzheimer's Failure

Nov 28

Alector, Inc.'s (NASDAQ:ALEC) Business And Shares Still Trailing The Industry

Oct 24
Alector, Inc.'s (NASDAQ:ALEC) Business And Shares Still Trailing The Industry

We Think Alector (NASDAQ:ALEC) Needs To Drive Business Growth Carefully

Sep 26
We Think Alector (NASDAQ:ALEC) Needs To Drive Business Growth Carefully

Alector, Inc.'s (NASDAQ:ALEC) Price Is Right But Growth Is Lacking

Jul 11
Alector, Inc.'s (NASDAQ:ALEC) Price Is Right But Growth Is Lacking

Alector, Inc. (NASDAQ:ALEC) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 11
Alector, Inc. (NASDAQ:ALEC) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Analysts Are Updating Their Alector, Inc. (NASDAQ:ALEC) Estimates After Its Full-Year Results

Mar 01
Analysts Are Updating Their Alector, Inc. (NASDAQ:ALEC) Estimates After Its Full-Year Results

The Market Doesn't Like What It Sees From Alector, Inc.'s (NASDAQ:ALEC) Revenues Yet As Shares Tumble 27%

Jan 19
The Market Doesn't Like What It Sees From Alector, Inc.'s (NASDAQ:ALEC) Revenues Yet As Shares Tumble 27%

Alector: Good Data, Huge Cash, No Near Term Catalyst

Jan 16

CEO Compensation Analysis

How has Arnon Rosenthal's remuneration changed compared to Alector's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$108m

Jun 30 2025n/an/a

-US$115m

Mar 31 2025n/an/a

-US$123m

Dec 31 2024US$4mUS$675k

-US$119m

Sep 30 2024n/an/a

-US$158m

Jun 30 2024n/an/a

-US$161m

Mar 31 2024n/an/a

-US$121m

Dec 31 2023US$4mUS$654k

-US$130m

Sep 30 2023n/an/a

-US$141m

Jun 30 2023n/an/a

-US$143m

Mar 31 2023n/an/a

-US$135m

Dec 31 2022US$4mUS$621k

-US$133m

Sep 30 2022n/an/a

-US$136m

Jun 30 2022n/an/a

US$36m

Mar 31 2022n/an/a

-US$29m

Dec 31 2021US$10mUS$575k

-US$36m

Sep 30 2021n/an/a

-US$33m

Jun 30 2021n/an/a

-US$212m

Mar 31 2021n/an/a

-US$202m

Dec 31 2020US$4mUS$554k

-US$190m

Sep 30 2020n/an/a

-US$169m

Jun 30 2020n/an/a

-US$148m

Mar 31 2020n/an/a

-US$127m

Dec 31 2019US$7mUS$525k

-US$105m

Sep 30 2019n/an/a

-US$92m

Jun 30 2019n/an/a

-US$76m

Mar 31 2019n/an/a

-US$62m

Dec 31 2018US$5mUS$397k

-US$52m

Compensation vs Market: Arnon's total compensation ($USD3.67M) is above average for companies of similar size in the US market ($USD1.47M).

Compensation vs Earnings: Arnon's compensation has been consistent with company performance over the past year.

CEO

Arnon Rosenthal (69 yo)

12.9yrs
Tenure
US$3,666,341
Compensation

Dr. Arnon Rosenthal, Ph D., Co-Founded Annexon in 2013 and serves as its Chief Executive Officer and Director since 2013 and served as its President since 2013. He served as Chief Scientific Officer of Ale...

Leadership Team

NamePositionTenureCompensationOwnership
Arnon Rosenthal
Co-Founder12.9yrsUS$3.67m5.19%
$ 8.2m
Neil Berkley
CFO & Chief Business Officerless than a yearno data0.073%
$ 116.2k
Katie Hogan
Senior Director of Corporate Communication & Investor Relationsno datano datano data
Danielle Pasqualone
General Counsel3.9yrsno datano data
Clare Hunt
Chief People Officerno datano datano data
Kristina Cutter
Chief Regulatoryno datano datano data
Virginia DeJesus-Rueff
Chief of Staff & Head of Strategy3.9yrsno datano data
Giacomo Salvadore
Chief Medical Officerless than a yearno datano data
3.9yrs
Average Tenure

Experienced Management: ALEC's management team is considered experienced (3.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Arnon Rosenthal
Co-Founder12.9yrsUS$3.67m5.19%
$ 8.2m
Louis Lavigne
Independent Chairperson of the Board7.2yrsUS$257.00k0.065%
$ 102.5k
Richard Scheller
Director & Member of Scientific Advisory Board7.2yrsUS$403.18k0.050%
$ 79.5k
Thomas Sudhof
Member of Scientific Advisory Boardno datano datano data
Stephen Hauser
Member of Scientific Advisory Boardno datano datano data
Mark Altmeyer
Independent Director1.8yrsUS$389.09k0.038%
$ 59.8k
Adam Boxer
Member of Scientific Advisory Boardno datano datano data
Paula Hammond
Independent Director5.8yrsUS$222.00k0.042%
$ 67.0k
Kristine Yaffe
Independent Director6.3yrsUS$219.50k0.061%
$ 96.7k
Michael Heneka
Member of Scientific Advisory Boardno datano datano data
Martin Kampmann
Member of Scientific Advisory Board3.9yrsno datano data
Elizabeth Garofalo
Independent Director4.3yrsUS$224.50k0.056%
$ 88.8k
6.0yrs
Average Tenure
68yo
Average Age

Experienced Board: ALEC's board of directors are considered experienced (6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/24 23:00
End of Day Share Price 2025/12/24 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Alector, Inc. is covered by 15 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alec StranahanBofA Global Research
Thomas ShraderBTIG
Pete StavropoulosCantor Fitzgerald & Co.